Genus plc (GNS), the global animal genetics and breeding company, has disclosed the purchase and cancellation of 83,620 ordinary shares of 10 pence each, acquired through J.P. Morgan Securities plc between 9 and 13 November 2026. The buyback was conducted across three trading days at prices ranging from 2,336 pence to 2,436 pence per share. The disclosure was made in accordance with UKLR 9.6.6R, the UK Listing Rules requirement governing companies' transactions in their own securities. Investors in Genus will note that all purchased shares are to be cancelled, reducing the total number of ordinary shares in issue.

Key Points

  • Genus plc (GNS) — global animal genetics business listed on the London Stock Exchange
  • The company purchased and will cancel 83,620 ordinary shares of 10 pence each between 9 and 13 November 2026
  • Volume weighted average prices ranged from 2,366.64 pence on 11 November to 2,406.75 pence on 9 November 2026
  • Investors should watch for further buyback tranches and any updated disclosure of shares remaining in issue

Genus Purchases 83,620 Shares Across Three Trading Days at Prices Up to 2,436 Pence

The announcement states that Genus acquired 28,956 shares on 9 November 2026 at a volume weighted average price (VWAP) of 2,406.7544 pence, with individual trade prices ranging from 2,384 pence to 2,424 pence. On 10 November, 27,649 shares were purchased at a VWAP of 2,400.3968 pence, with prices between 2,346 pence and 2,436 pence. On 11 November, the company acquired a further 27,015 shares at a VWAP of 2,366.6416 pence, within a range of 2,336 pence to 2,386 pence. All transactions were executed through J.P. Morgan Securities plc acting as the company's broker for the programme.

All Repurchased Genus Shares to Be Cancelled, Reducing Ordinary Share Capital

The announcement confirms that all 83,620 shares purchased during this period will be cancelled rather than held in treasury. Cancellation of repurchased shares directly reduces a company's total ordinary share capital in issue, which can affect per-share financial metrics such as earnings per share over time. Genus is a specialist in bovine and porcine genetics, operating across multiple international markets, and uses its proprietary breeding technologies to serve livestock producers globally. The buyback and cancellation form part of the company's capital management activity, conducted under applicable UK regulatory requirements governing market purchases of own securities.

Regulatory Compliance Under UKLR 9.6.6R and UK Market Abuse Regulation Framework

The disclosure was made pursuant to UKLR 9.6.6R and Article 5(1)(b) of Regulation (EU) No 596/2014, which now forms part of UK domestic law following the European Union (Withdrawal) Act 2018. These rules require listed companies to publish aggregated and disaggregated details of share buyback transactions on the trading day following execution. Genus has provided a link to the full disaggregated trade-by-trade data via the London Stock Exchange's RNS platform, allowing investors and regulators to scrutinise individual transaction timing, volumes, and prices in full. Genus did not disclose the total size or duration of the broader buyback programme in this announcement.